AVITA Medical, Inc. (ASX:AVH)
Australia · Delayed Price · Currency is AUD | Market Cap | 180.29M -53.4% |
| Revenue (ttm) | 105.41M +1.0% |
| Net Income | -66.06M |
| EPS | -2.28 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 251,507 |
| Average Volume | 185,852 |
| Open | 1.170 |
| Previous Close | 1.230 |
| Day's Range | 1.135 - 1.175 |
| 52-Week Range | 1.000 - 2.180 |
| Beta | 1.90 |
| RSI | 50.51 |
| Earnings Date | May 14, 2026 |
About AVITA Medical
AVITA Medical, Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a device that enables healthcare professionals t... [Read more]
Financial Performance
In 2025, AVITA Medical's revenue was $71.61 million, an increase of 11.45% compared to the previous year's $64.25 million. Losses were -$48.59 million, -21.44% less than in 2024.
Financial numbers in USD Financial StatementsNews
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholder...
Avita Medical upgraded to Buy from Hold at Lake Street
Lake Street upgraded Avita Medical (RCEL) to Buy from Hold with a price target of $6, up from $3.50. Q1 was Avita’s highest revenue quarter since mid-2024, which the firm…
Avita Medical reports Q1 EPS (35c), consensus (38c)
Reports Q1 revenue $19.3M, consensus $24.65M. Cary Vance, CEO, commented: “Since November, we’ve stabilized the business, improved how we operate, and delivered a solid start to 2026. With sequential ...
Avita Medical reiterates FY26 revenue guidance of $80M-$85M, consensus $116.97M
FY26 revenue is expected to be in the range of $80M-$85M, representing growth of approximately 12%-19% compared to FY25 revenue.
AVITA Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4% year-over-year and 10% sequentially, driven by RECELL and Cohealyx adoption, with gross margin at 81.7% and operating expenses down 11%. Full-year guidance of $80–$85 million was reaffirmed, and cash use is expected to decrease in Q2.
AVITA Medical Reports First Quarter 2026 Financial Results
VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” o...
Avita Medical appoints Cary Vance as CEO
Avita Medical (RCEL) announced that its board of directors has appointed Cary Vance as president and CEO, effective immediately. The board of directors has also appointed Jan Stern Reed as…
AVITA Medical Names Cary Vance as Chief Executive Officer
Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board...
Avita Medical receives regulatory clearance for Recell Go
Avita Medical (RCEL) announced that Recell Go, its next-generation system for preparing Recell Spray-On Skin, has received certification from Australia’s Therapeutic Goods Administration and has been ...
AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
RECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both markets RECELL GO is AVITA Medical's next-generation system that automates and standardize...
AVITA Medical to Announce First Quarter 2026 Financial Results
VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarte...
AVITA Medical Transcript: KOL event
Interim results from the Cohealyx-I study show a significant reduction in time to grafting, with a mean of 13.6 days versus 33 days for traditional matrices. Surgeons report high satisfaction, workflow integration, and anticipate broader adoption due to improved outcomes and cost efficiency.
AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
Recognition highlights pioneering contributions to modern burn care including development of RECELL ® Spray-On Skin™ VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: ...
Avita Medical announces interim results from Cohealyx-I multi-center study
Avita Medical (RCEL) announced interim results from its Cohealyx-I multi-center study demonstrating a reduction of nearly 20 days in mean time to skin grafting for patients with full-thickness wounds....
AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
Cohealyx interim data show ~20-day reduction in time to graft vs benchmark, with strong investigator satisfaction and consistent performance across wounds.
AVITA Medical, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AVITA Medical, Inc. , (“ AVITA " or the "Company") ( NASDAQ : RCEL) investors that the firm has initiated an investigation...
Avita Medical secures 10-year BARDA agreement worth $25.5M
Avita Medical (RCEL) announced it has entered into a 10-year agreement with the Biomedical Advanced Research and Development Authority, or BARDA, part of the Administration for Strategic Preparedness ...
AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
AVITA Medical highlights new Cohealyx data and real-world evidence at upcoming ABA 2026, advancing wound healing and improving patient recovery outcomes
Avita Medical stock pullback creates buying opportunity, says Northland
Northland tells investors in a research note that the 20% pullback in Avita Medical’s (RCEL) stock creates a buying opportunity. Reimbursement uncertainty that limited FY25 growth to 11% has eased,…
Avita Medical initiated with an Outperform at Northland
Northland initiated coverage of Avita Medical (RCEL) with an Outperform rating and $10 price target With about 5% penetration of a roughly $1.3B total addressable market, differentiated products, and ...
Avita Medical initiated with an Outperform at Northland
Northland initiated coverage of Avita Medical (RCEL) with an Outperform rating and $10 price target
AVITA Medical Transcript: TD Cowen 46th Annual Health Care Conference
The company is targeting deeper penetration in acute wound care with three synergistic products, expecting sequential growth and improved margins as reimbursement normalizes and VAC approvals expand. Ongoing clinical studies and a data-driven approach support further adoption and profitability.
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference
VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced C...
AVITA Medical Transcript: Status update
Disciplined execution and cost control have positioned the business for 2026 revenue growth, with guidance set at $80–$85 million and a focus on expanding product adoption. New credit facilities and resolved reimbursement issues provide stability, while operational priorities remain on revenue growth and profitability.
Avita Medical reports Q4 EPS (38c), consensus (55c)
Reports Q4 revenue $17.62M, consensus $25.23M. Cary Vance, interim CEO of Avita Medical (RCEL), commented: “The fourth quarter marked the close of a year of stabilization, and the beginning of…